Bank of America closed Tuesday at $59.86, up 5% on the week and within striking distance of multi-year highs, as the final analyst target-raise wave washes through ahead of the July 14 Q2 print.
The options market has quietly reached its most constructive posture of the year. The put/call ratio fell to 1.08 — essentially matching the 52-week low — and running nearly a full standard deviation below its 20-day average of 1.21. Mid-June told a different story: the PCR was pushing 1.50, signalling heavy demand for downside protection. That hedging has been almost entirely unwound. Short interest is equally benign: at 1.36% of the free float, it has drifted slightly higher on the week but remains near its lowest readings of the past three months, down roughly 13% from the mid-June peak above 115 million shares. Borrow availability is unconstrained — at the top of the measurement range — and the cost to borrow, though volatile, eased 28% on the week to just 0.36%. There is no squeeze dynamic, no accumulation of short conviction. Positioning looks as clean as it has all year.
The analyst wave has not stopped. UBS's Erika Najarian raised her target to $68 from $63 yesterday, maintaining Buy. That follows JP Morgan's Vivek Juneja lifting to $62.50 and Wells Fargo's Mike Mayo moving to $67, both filed on Monday morning — the same two firms flagged in last week's note. Evercore also moved targets higher. The mean consensus price target now sits at $65.31, against a close of $59.86, implying roughly 9% further upside from here on the Street's central case. The lone counter-move came from Oppenheimer, which stepped down to Perform from Outperform on June 30 — but that read has been largely drowned out by the volume of upgrades around it. At 12.1x trailing earnings and 1.38x book, the valuation has re-rated meaningfully: the price-to-book multiple expanded by roughly 0.13 over the past 30 days. The dividend yield factor ranks in the 93rd percentile, and EPS surprise sits at the 75th percentile — both consistent with a franchise that has been systematically beating the bar.
The institutional picture supports that framing. BlackRock added roughly 4.75 million shares as of June 30, and Capital Research added another 8.5 million, making them the two most active builders among the top-ten holders. Berkshire Hathaway trimmed modestly in Q1 — 3.7 million shares — but still holds 7.24% of the company. Insider activity has been routine rather than signal-bearing: CEO Brian Moynihan's monthly award-and-sell pattern continued in June at $55.87 per share, well below where the stock trades now, but the transactions are mechanical and carry no discretionary read-through. The Chief Risk Officer sold $6.7 million of stock in early May — a larger transaction — though that was at $53, also below current levels.
Closest peers moved broadly in line on the week. WFC gained 4.4% and JPM added 3%, both tightly correlated to BAC's trajectory. C was the notable exception, falling 1.2% on the week and dropping another 2.1% Tuesday alone — suggesting some single-name noise in the sector rather than a macro divergence.
The last concrete earnings reaction data point is April 15, when BAC opened up 0.3% on the day but drifted 0.4% lower over the following five sessions. The Q2 setup — price 11% higher, analyst targets clustered $62-68, options at their most call-heavy of the year — is materially different. What to watch on July 14 is less whether net interest income grows and more whether the NII trajectory convinces the Street that the repricing already embedded in analyst models is durable, or whether credit quality commentary introduces a reason to revisit it.
See the live data behind this article on ORTEX.
Open BAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
